Latest osteosarcoma Stories
IRVINE, Calif., Sept. 26 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.
SAN MARINO, Calif., Sept. 15 /PRNewswire/ -- Epeius Biotechnologies Corporation today announced that Rexin-G, its lead product in development for metastatic cancer, has been highlighted in a recent NEWS article published by the Journal of the National Cancer Institute (JNCI, Sept. 9, 2008).
By Chotel, F Unnithan, A; Chandrasekar, C R; Parot, R; Jeys, L; Grimer, R J We have analysed the pattern of symptoms in patients presenting with synovial sarcoma to identify factors which led to long delays in diagnosis.
NASHVILLE, Tenn., Aug. 12 /PRNewswire/ -- A drug widely used to treat high cholesterol is helping beat cancer. Lovastatin is part of a new cancer treatment that has arrested or eradicated tumors in more than 80% of initial patients.
By Litzky, Leslie A * Context.-Sarcomatous pulmonary neoplasms are a rare and diagnostically challenging group of tumors.
By Dishop, Megan K Kuruvilla, Supriya * Context.-Primary lung neoplasms are rare in children, but they comprise a broad and interesting spectrum of lesions, some of which are familiar from other tissue sites, and some of which are unique to the pediatric lung.
NASHVILLE, Tenn., July 14 /PRNewswire/ -- A newly available treatment already has benefited several individuals with aggressive malignancies. Offered through NeoPlas Innovation, this regimen has arrested or eradicated tumors in more than 80% of initial patients. Director of Research Dr.
By Daniel Axelrod, The Times-Tribune, Scranton, Pa. Jul. 12--TOBYHANNA -- State officials investigating if four Pocono Mountain-area teenagers represent a "cluster" of rare bone cancers have reopened their analysis based on a Sunday Times story.
Epeius Biotechnologies has announced that Rexin-G has received orphan drug designation from the FDA for the treatment of osteosarcoma.
SAN MARINO, Calif., July 8 /PRNewswire/ -- Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma.
- Growing in low tufty patches.